Call Options

2 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2023

May 12, 2023

BUY
$4.19 - $16.83 $1.05 Million - $4.21 Million
250,000 Added 250.0%
350,000 $1.48 Million
Q3 2022

Nov 14, 2022

BUY
$10.67 - $22.41 $1.07 Million - $2.24 Million
100,000 New
100,000 $1.28 Million

Others Institutions Holding ALT

About Altimmune, Inc.


  • Ticker ALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,025,300
  • Market Cap $404M
  • Description
  • Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...
More about ALT
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.